RxDoctor Payments Data

Brandon Barney, MD

Radiation Oncology · American Fork, UTNPI 1194961789

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $11,755 of the $15,999 with a category attached, or 73.5%. Myovant Sciences Inc. accounts for 80.5% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $13,847 and has fallen 93.8% since, to $860 in 2025. Among radiation oncology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,999in general payments, 2019–2025

Across 40 payments — averaging $399.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Myovant Sciences Inc.$13K
  • Reflexion Medical, Inc.$1K
  • IBA Proton Therapy, Inc.$645
  • Siemens Medical Solutions USA, Inc.$372
  • Novocure Inc.$240
  • Boston Scientific$122
  • plus $312 from 9 others
$60,853in research payments, 2019–2025

Across 19 payments — averaging $3202.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sumitomo Pharma America, Inc.$61K

What the payments were for

  • Speaking & faculty fees$11,75573%
  • Travel & lodging$1,99512%
  • Food & beverage$2,24914%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,999 in reported general payments places this provider in the 95th percentile of 49 radiation oncology providers in Utah.

See all radiation oncology providers in Utah

Medicare billing

Part B allowed, 2024
$119,171
Medicare patients
169
Services billed
1,221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron13$5,809
Tamsulosin Hcl98$1,528
Bicalutamide17$227
Ciprofloxacin Hcl35$112

Paid to pharmacies, not to this prescriber.

Other radiation oncology in American Fork

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →